1. Home
  2. VIVS vs ACON Comparison

VIVS vs ACON Comparison

Compare VIVS & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIVS
  • ACON
  • Stock Information
  • Founded
  • VIVS 2007
  • ACON 2008
  • Country
  • VIVS United States
  • ACON United States
  • Employees
  • VIVS N/A
  • ACON N/A
  • Industry
  • VIVS Biotechnology: Biological Products (No Diagnostic Substances)
  • ACON Retail: Computer Software & Peripheral Equipment
  • Sector
  • VIVS Health Care
  • ACON Technology
  • Exchange
  • VIVS Nasdaq
  • ACON Nasdaq
  • Market Cap
  • VIVS 4.2M
  • ACON 4.1M
  • IPO Year
  • VIVS N/A
  • ACON 2022
  • Fundamental
  • Price
  • VIVS $1.60
  • ACON $7.33
  • Analyst Decision
  • VIVS
  • ACON Buy
  • Analyst Count
  • VIVS 0
  • ACON 2
  • Target Price
  • VIVS N/A
  • ACON $481.00
  • AVG Volume (30 Days)
  • VIVS 42.9K
  • ACON 15.9K
  • Earning Date
  • VIVS 07-11-2025
  • ACON 08-13-2025
  • Dividend Yield
  • VIVS N/A
  • ACON N/A
  • EPS Growth
  • VIVS N/A
  • ACON N/A
  • EPS
  • VIVS N/A
  • ACON N/A
  • Revenue
  • VIVS $144,000.00
  • ACON $54,601.00
  • Revenue This Year
  • VIVS $42.38
  • ACON $212.31
  • Revenue Next Year
  • VIVS $15.42
  • ACON $92.86
  • P/E Ratio
  • VIVS N/A
  • ACON N/A
  • Revenue Growth
  • VIVS 32.11
  • ACON N/A
  • 52 Week Low
  • VIVS $1.41
  • ACON $6.20
  • 52 Week High
  • VIVS $21.96
  • ACON $3,499.51
  • Technical
  • Relative Strength Index (RSI)
  • VIVS N/A
  • ACON 40.87
  • Support Level
  • VIVS N/A
  • ACON $7.30
  • Resistance Level
  • VIVS N/A
  • ACON $8.19
  • Average True Range (ATR)
  • VIVS 0.00
  • ACON 0.37
  • MACD
  • VIVS 0.00
  • ACON 0.32
  • Stochastic Oscillator
  • VIVS 0.00
  • ACON 57.86

About VIVS VivoSim Labs Inc. Common Stock

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

About ACON Aclarion Inc.

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Share on Social Networks: